-
- Matthew McCallum
- Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
-
- Alexandra C. Walls
- Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
-
- Kaitlin R. Sprouse
- Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
-
- John E. Bowen
- Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
-
- Laura E. Rosen
- Vir Biotechnology, San Francisco, CA 94158, USA.
-
- Ha V. Dang
- Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
-
- Anna De Marco
- Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
-
- Nicholas Franko
- Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA.
-
- Sasha W. Tilles
- Center for Emerging and Re-emerging Infectious Diseases, Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA.
-
- Jennifer Logue
- Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA.
-
- Marcos C. Miranda
- Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
-
- Margaret Ahlrichs
- Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
-
- Lauren Carter
- Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
-
- Gyorgy Snell
- Vir Biotechnology, San Francisco, CA 94158, USA.
-
- Matteo Samuele Pizzuto
- Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
-
- Helen Y. Chu
- Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA.
-
- Wesley C. Van Voorhis
- Center for Emerging and Re-emerging Infectious Diseases, Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA.
-
- Davide Corti
- Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
-
- David Veesler
- Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
抄録
<jats:title>How the Delta variant evades defenses</jats:title> <jats:p> In the course of the COVID-19 epidemic, variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to emerge, some of which evade immunity or increase transmission. In late 2020, the Delta and Kappa variants were detected, and the Delta variant became globally dominant by June 2021. McCallum <jats:italic>et al</jats:italic> . show that vaccine-elicited serum-neutralizing activity is reduced against these variants. Based on biochemistry and structural studies, the authors show that mutations in the domain that binds the ACE2 receptor abrogate binding to some monoclonal antibodies but do not improve ACE2 binding, suggesting that they emerged to escape immune recognition. Remodeling of the N-terminal domain allows the variants to escape recognition by most neutralizing antibodies that target it. The work could guide the development of next-generation vaccines and antibody therapies. —VV </jats:p>
収録刊行物
-
- Science
-
Science 374 (6575), 1621-1626, 2021-12-24
American Association for the Advancement of Science (AAAS)